Atea Pharmaceuticals Analyst Ratings
Atea Pharmaceuticals Analyst Ratings
雅泰醫藥分析師評級
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 01/24/2023 | -15.79% | Morgan Stanley | $7 → $4 | Maintains | Underweight |
| 08/15/2022 | 47.37% | Morgan Stanley | $6 → $7 | Maintains | Underweight |
| 03/02/2022 | 68.42% | JP Morgan | $10 → $8 | Maintains | Neutral |
| 03/01/2022 | 89.47% | SVB Leerink | $10 → $9 | Maintains | Market Perform |
| 02/16/2022 | 110.53% | SVB Leerink | $11 → $10 | Maintains | Market Perform |
| 01/06/2022 | 47.37% | Morgan Stanley | $14 → $7 | Downgrades | Equal-Weight → Underweight |
| 11/18/2021 | 131.58% | SVB Leerink | → $11 | Downgrades | Outperform → Market Perform |
| 10/20/2021 | 321.05% | SVB Leerink | $60 → $20 | Maintains | Outperform |
| 10/20/2021 | 236.84% | JP Morgan | $61 → $16 | Downgrades | Overweight → Neutral |
| 10/05/2021 | 1057.89% | Morgan Stanley | → $55 | Downgrades | Overweight → Equal-Weight |
| 09/09/2021 | 1163.16% | SVB Leerink | → $60 | Initiates Coverage On | → Outperform |
| 08/18/2021 | 678.95% | Morgan Stanley | $35 → $37 | Maintains | Overweight |
| 06/03/2021 | 636.84% | Morgan Stanley | $82 → $35 | Maintains | Overweight |
| 04/06/2021 | 1626.32% | Morgan Stanley | $49 → $82 | Maintains | Overweight |
| 01/29/2021 | 1289.47% | JP Morgan | $45 → $66 | Maintains | Overweight |
| 11/25/2020 | — | Evercore ISI Group | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 847.37% | JP Morgan | → $45 | Initiates Coverage On | → Overweight |
| 11/24/2020 | — | William Blair | Initiates Coverage On | → Outperform | |
| 11/24/2020 | 931.58% | Morgan Stanley | → $49 | Initiates Coverage On | → Overweight |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 01/24/2023 | -15.79% | 摩根士丹利 | $7→$4 | 維護 | 體重不足 |
| 2022年08月15日 | 47.37% | 摩根士丹利 | $6→$7 | 維護 | 體重不足 |
| 03/02/2022 | 68.42% | 摩根大通 | $10→$8 | 維護 | 中性 |
| 03/01/2022 | 89.47% | SVB Leerink | $10→$9 | 維護 | 市場表現 |
| 02/16/2022 | 110.53% | SVB Leerink | $11→$10 | 維護 | 市場表現 |
| 01/06/2022 | 47.37% | 摩根士丹利 | $14→$7 | 評級下調 | 等重→減碼 |
| 2021年11月18日 | 131.58% | SVB Leerink | →$11 | 評級下調 | 跑贏→市場表現 |
| 10/20/2021 | 321.05% | SVB Leerink | $60→$20 | 維護 | 跑贏大盤 |
| 10/20/2021 | 236.84% | 摩根大通 | $61→$16 | 評級下調 | 超重→中性 |
| 10/05/2021 | 1057.89% | 摩根士丹利 | →$55 | 評級下調 | 超重→等重 |
| 09/09/2021 | 1163.16% | SVB Leerink | →$60 | 開始承保 | →跑贏大盤 |
| 2021/08/18 | 678.95% | 摩根士丹利 | $35→$37 | 維護 | 超重 |
| 06/03/2021 | 636.84% | 摩根士丹利 | $82→$35 | 維護 | 超重 |
| 04/06/2021 | 1626.32% | 摩根士丹利 | $49→$82 | 維護 | 超重 |
| 2021/01/29 | 1289.47% | 摩根大通 | $45→$66 | 維護 | 超重 |
| 11/25/2020 | - | Evercore ISI集團 | 開始承保 | →跑贏大盤 | |
| 11/24/2020 | 847.37% | 摩根大通 | →$45 | 開始承保 | →超重 |
| 11/24/2020 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 11/24/2020 | 931.58% | 摩根士丹利 | →$49 | 開始承保 | →超重 |
What is the target price for Atea Pharmaceuticals (AVIR)?
ATEA製藥(Avir)的目標價是多少？
There is no price target for Atea Pharmaceuticals
ATEA製藥公司沒有目標價格
What is the most recent analyst rating for Atea Pharmaceuticals (AVIR)?
分析師對安泰製藥(AVIR)的最新評級是多少？
There is no analyst for Atea Pharmaceuticals
ATEA製藥公司沒有分析師
When is the next analyst rating going to be posted or updated for Atea Pharmaceuticals (AVIR)?
安泰製藥(Avir)的下一次分析師評級將於何時發佈或更新？
There is no next analyst rating for Atea Pharmaceuticals
沒有下一個分析師對ATEA製藥的評級
Is the Analyst Rating Atea Pharmaceuticals (AVIR) correct?
分析師對安泰製藥(AVIR)的評級正確嗎？
There is no next analyst rating for Atea Pharmaceuticals
沒有下一個分析師對ATEA製藥的評級